These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Soluble prion protein and its N-terminal fragment prevent impairment of synaptic plasticity by Aβ oligomers: Implications for novel therapeutic strategy in Alzheimer's disease. Scott-McKean JJ; Surewicz K; Choi JK; Ruffin VA; Salameh AI; Nieznanski K; Costa ACS; Surewicz WK Neurobiol Dis; 2016 Jul; 91():124-131. PubMed ID: 26949218 [TBL] [Abstract][Full Text] [Related]
6. Implications of Metal Binding and Asparagine Deamidation for Amyloid Formation. Sadakane Y; Kawahara M Int J Mol Sci; 2018 Aug; 19(8):. PubMed ID: 30126231 [TBL] [Abstract][Full Text] [Related]
7. High molecular mass assemblies of amyloid-β oligomers bind prion protein in patients with Alzheimer's disease. Dohler F; Sepulveda-Falla D; Krasemann S; Altmeppen H; Schlüter H; Hildebrand D; Zerr I; Matschke J; Glatzel M Brain; 2014 Mar; 137(Pt 3):873-86. PubMed ID: 24519981 [TBL] [Abstract][Full Text] [Related]
8. Binding Sites for Amyloid-β Oligomers and Synaptic Toxicity. Smith LM; Strittmatter SM Cold Spring Harb Perspect Med; 2017 May; 7(5):. PubMed ID: 27940601 [TBL] [Abstract][Full Text] [Related]
9. Prion Protein Interactome: Identifying Novel Targets in Slowly and Rapidly Progressive Forms of Alzheimer's Disease. Zafar S; Shafiq M; Younas N; Schmitz M; Ferrer I; Zerr I J Alzheimers Dis; 2017; 59(1):265-275. PubMed ID: 28671123 [TBL] [Abstract][Full Text] [Related]
10. Variable tau accumulation in murine models with abnormal prion protein deposits. Piccardo P; King D; Brown D; Barron RM J Neurol Sci; 2017 Dec; 383():142-150. PubMed ID: 29246602 [TBL] [Abstract][Full Text] [Related]
11. Amyloidogenesis of Tau protein. Nizynski B; Dzwolak W; Nieznanski K Protein Sci; 2017 Nov; 26(11):2126-2150. PubMed ID: 28833749 [TBL] [Abstract][Full Text] [Related]
12. Functions of the Prion Protein. Hirsch TZ; Martin-Lannerée S; Mouillet-Richard S Prog Mol Biol Transl Sci; 2017; 150():1-34. PubMed ID: 28838656 [TBL] [Abstract][Full Text] [Related]
15. Pathogenic mechanisms of prion protein, amyloid-β and α-synuclein misfolding: the prion concept and neurotoxicity of protein oligomers. Ugalde CL; Finkelstein DI; Lawson VA; Hill AF J Neurochem; 2016 Oct; 139(2):162-180. PubMed ID: 27529376 [TBL] [Abstract][Full Text] [Related]
17. Familial human prion diseases associated with prion protein mutations Y226X and G131V are transmissible to transgenic mice expressing human prion protein. Race B; Williams K; Hughson AG; Jansen C; Parchi P; Rozemuller AJM; Chesebro B Acta Neuropathol Commun; 2018 Feb; 6(1):13. PubMed ID: 29458424 [TBL] [Abstract][Full Text] [Related]
18. Molecular pathogenesis of beta-amyloidosis in Alzheimer's disease and other cerebral amyloidoses. Maury CP Lab Invest; 1995 Jan; 72(1):4-16. PubMed ID: 7837789 [No Abstract] [Full Text] [Related]
19. The biological function of the cellular prion protein: an update. Wulf MA; Senatore A; Aguzzi A BMC Biol; 2017 May; 15(1):34. PubMed ID: 28464931 [TBL] [Abstract][Full Text] [Related]
20. Effects of peptidyl-prolyl isomerase 1 depletion in animal models of prion diseases. Legname G; Virgilio T; Bistaffa E; De Luca CMG; Catania M; Zago P; Isopi E; Campagnani I; Tagliavini F; Giaccone G; Moda F Prion; 2018 Mar; 12(2):127-137. PubMed ID: 29676205 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]